CHICAGO — The multidrug-resistant Streptococcus pneumoniae serotype 19A continues to spread across the United States, according to a study led by Dr. David J. Farrell.
“And we believe that that the emergence of this 19A clone has been driven by the 7-valent pneumococcal conjugate vaccine,” Dr. Farrell said in an interview during a poster presentation at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Dr. Farrell, director of clinical microbiology at G.R. Micro Ltd., a London-based company that does contract research for pharmaceutical companies, and his colleagues collected more than 21,000 S. pneumoniae samples from 103 U.S. centers within the 4 years of the global PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study.
In all, 562 of the isolates were the multidrug-resistant (MDR) 19A strain, Dr. Farrell said at the meeting, which was sponsored by the American Society for Microbiology.
Between 2002 and 2006, the proportion of isolates that were MDR 19A increased from 1% to 6%. The largest proportion was in the group aged 0-2 years (rising from 4% to 15%), followed by the group aged 3-14 years (1% to nearly 9%). In the group of those aged at least 65 years, MDR 19A accounted for 3% of all isolates in 2005-2006, said Dr. Farrell in an interview.
“So we've got this 19A serotype that's not in the vaccine, it's being driven by the vaccine, and it's becoming more prevalent and spilling over to older children and adults, including the elderly population.”
A second study examining antimicrobial resistance patterns among S. pneumoniae isolated from children showed that the experimental oral penem antibiotic, faropenem, was the most potent oral β-lactam based on in vitro activity.
During the 2005-2006 respiratory season, S. pneumoniae isolates were prospectively collected from 104 participating institutions distributed across the United States as part of the faropenem surveillance (FAMOUS) study. In total, 393 isolates were collected from children aged 6-14 years, 3-5 years, and younger than 2 years.
The isolates were then tested for susceptibility to faropenem, meropenem, amoxicillin/clavulanate, cefdinir, cefuroxime, penicillin, azithromycin, levofloxacin, and trimethoprim/sulfamethoxazole.
Multidrug resistance was defined as resistance to either two or three of these agents, said Ian A. Critchley, Ph.D., the director of microbiology at Replidyne Inc., in Louisville, Colo., which is evaluating faropenem.
Of the 393 S. pneumoniae isolates from children younger than age 14 years, half were penicillin susceptible, one-fourth were penicillin intermediate, and another fourth were penicillin resistant, the authors stated.
Faropenem was the most active b-lactam against all pediatric isolates, with a minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC90) of 1 mcg/mL. The MIC90 of both amoxicillin/clavulanate and cefdinir was 8 mcg/mL.
The least effective agents were penicillin, azithromycin, and trimethoprim/sulfamethoxazole, with percent-susceptible rates of 49, 55, and 57, respectively.
Antimicrobial resistance was generally higher among isolates from children aged younger than 2 years, compared with isolates from those aged 6-14 years, the authors reported.
Penicillin resistance ranged from 15% among isolates from children aged 6-14 years to 31% among isolates from children younger than 2 years.
“Among children under age 2 years, [in whom] there's been wide use of b-lactams and macrolides, we saw that the penem compound holds out very favorably in our in vitro minimum inhibitory concentration (MIC) profile, when compared with amoxicillin/clavulanate and cefdinir,” said Dr. Critchley. Among the S. pneumoniae resistant to three classes of agents, only 29% were susceptible to amoxicillin/clavulanate, and none of the isolates was susceptible to cefdinir, he said.
In a separate comment, Dr. Stephen I. Pelton said MDR 19A should be suspected in children with persisting signs and symptoms of acute otitis media despite antimicrobial therapy.
“Some of these isolates will be susceptible to high-dose Augmentin or a three-dose regimen of intramuscular ceftriaxone, but others may not,” said Dr. Pelton, chief of pediatric infectious disease at Boston Medical Center.
Tympanocentesis with or without tube insertion will offer symptomatic benefit for those with treatment failure or persistent earache, irritability, or other symptoms, Dr. Pelton said in an interview. “The 19A strain was intermediate resistant in 2000, and it is both the [PCV7] vaccine's lack of cross-reactivity and the presence of resistance that has selected for the increase in 19A,” he said.
Between 2002 and 2006, the proportion of isolates that were MDR 19A increased from 1% to 6%. DR. FARRELL